Diaceutics’ (DXRX) “Buy” Rating Reaffirmed at Canaccord Genuity Group

Canaccord Genuity Group reiterated their buy rating on shares of Diaceutics (LON:DXRX) in a research report report published on Tuesday morning,Digital Look reports. Canaccord Genuity Group currently has a GBX 215 price target on the stock.

Diaceutics Stock Performance

Shares of LON DXRX opened at GBX 186 on Tuesday. The business’s 50-day simple moving average is GBX 145.97 and its 200-day simple moving average is GBX 150.95. The company has a debt-to-equity ratio of 2.85, a quick ratio of 9.92 and a current ratio of 3.43. Diaceutics has a 52 week low of GBX 125 and a 52 week high of GBX 186.90. The firm has a market cap of £157.84 million, a price-to-earnings ratio of 1,690.91 and a beta of 0.88.

Diaceutics (LON:DXRX) last announced its earnings results on Tuesday, September 22nd. The company reported GBX (3.27) EPS for the quarter. Diaceutics had a return on equity of 0.25% and a net margin of 0.25%. As a group, equities research analysts expect that Diaceutics will post 1.0107919 earnings per share for the current fiscal year.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.